SHARE INFORMATION ABOUT THE DEADLY THREAT OF ADVANCED PROSTATE CANCER IN THE BONE

Fill out the fields below to share information with your colleagues.

Fields marked with an (*) are required.

 

Subject: Information about confronting the deadly threat of prostate cancer in the bone

E-mail addresses will be used solely to send this information. Bayer will not retain or sell e-mail addresses or personal information.

References: 1. Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162-167. 2. Gandaglia G, Karakiewicz PI, Briganti A, et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol. 2015;68(2):325-334. 3. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther. 2007;6(10):2609-2617. 4. Bagi CM. Skeletal implications of prostate cancer. J Musculoskelet Neuronal Interact. 2003;3(2):112-117. 5. Gundem G, Van Loo P, Kremeyer B, et al; ICGC Prostate UK Group. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520(7547):353-357.

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

© 2020 Bayer. All rights reserved. BAYER and the Bayer Cross are registered trademarks of Bayer. All other trademarks are property of their respective owners. These trademark owners are not affiliated with Bayer and do not sponsor or endorse Bayer.

Site Last Modified: 12/2020